Published in N Engl J Med on May 24, 2001
Toward unraveling the complexity of simple epithelial keratins in human disease. J Clin Invest (2009) 2.34
Simple epithelium keratins 8 and 18 provide resistance to Fas-mediated apoptosis. The protection occurs through a receptor-targeting modulation. J Cell Biol (2001) 1.73
A disease- and phosphorylation-related nonmechanical function for keratin 8. J Cell Biol (2006) 1.68
Keratins in health and cancer: more than mere epithelial cell markers. Oncogene (2010) 1.61
"IF-pathies": a broad spectrum of intermediate filament-associated diseases. J Clin Invest (2009) 1.55
Keratin binding to 14-3-3 proteins modulates keratin filaments and hepatocyte mitotic progression. Proc Natl Acad Sci U S A (2002) 1.32
Keratin 20 helps maintain intermediate filament organization in intestinal epithelia. Mol Biol Cell (2003) 1.29
Keratin variants predispose to acute liver failure and adverse outcome: race and ethnic associations. Gastroenterology (2010) 1.28
Gastrointestinal differentiation marker Cytokeratin 20 is regulated by homeobox gene CDX1. Proc Natl Acad Sci U S A (2009) 1.20
Cytoskeletal keratin glycosylation protects epithelial tissue from injury. Nat Cell Biol (2010) 1.18
Pairwise assembly determines the intrinsic potential for self-organization and mechanical properties of keratin filaments. Mol Biol Cell (2002) 1.17
Keratin variants are overrepresented in primary biliary cirrhosis and associate with disease severity. Hepatology (2009) 1.08
Keratin mutation predisposes to mouse liver fibrosis and unmasks differential effects of the carbon tetrachloride and thioacetamide models. Gastroenterology (2008) 1.07
Keratins modulate the shape and function of hepatocyte mitochondria: a mechanism for protection from apoptosis. J Cell Sci (2009) 1.04
Bile acid-induced Mallory body formation in drug-primed mouse liver. Am J Pathol (2002) 1.03
Autoantibody-negative autoimmune hepatitis. Dig Dis Sci (2011) 1.03
Keratins modulate c-Flip/extracellular signal-regulated kinase 1 and 2 antiapoptotic signaling in simple epithelial cells. Mol Cell Biol (2004) 1.01
Keratin hypersumoylation alters filament dynamics and is a marker for human liver disease and keratin mutation. J Biol Chem (2010) 1.00
Keratin 8 and 18 mutations are risk factors for developing liver disease of multiple etiologies. Proc Natl Acad Sci U S A (2003) 1.00
Intermediate filament cytoskeleton of the liver in health and disease. Histochem Cell Biol (2008) 0.99
Absence of keratin 8 confers a paradoxical microflora-dependent resistance to apoptosis in the colon. Proc Natl Acad Sci U S A (2011) 0.94
Disorders of keratinisation: from rare to common genetic diseases of skin and other epithelial tissues. Ulster Med J (2007) 0.92
Cytokeratins as targets for bile acid-induced toxicity. Am J Pathol (2002) 0.91
Mallory-Denk bodies are associated with outcomes and histologic features in patients with chronic hepatitis C. Clin Gastroenterol Hepatol (2011) 0.90
Reg-II is an exocrine pancreas injury-response product that is up-regulated by keratin absence or mutation. Mol Biol Cell (2007) 0.88
A role for disulfide bonding in keratin intermediate filament organization and dynamics in skin keratinocytes. J Cell Biol (2015) 0.87
Unique amino acid signatures that are evolutionarily conserved distinguish simple-type, epidermal and hair keratins. J Cell Sci (2012) 0.84
Genetic disorders of palm skin and nail. J Anat (2003) 0.84
Keratin 8 expression in head and neck epithelia. BMC Cancer (2008) 0.84
Label-free proteomics reveals decreased expression of CD18 and AKNA in peripheral CD4+ T cells from patients with Vogt-Koyanagi-Harada syndrome. PLoS One (2011) 0.83
Heat shock protein 70 expression, keratin phosphorylation and Mallory body formation in hepatocytes from griseofulvin-intoxicated mice. Comp Hepatol (2004) 0.83
Non-coding keratin variants associate with liver fibrosis progression in patients with hemochromatosis. PLoS One (2012) 0.82
Keratin 8 expression in colon cancer associates with low faecal butyrate levels. BMC Gastroenterol (2011) 0.81
Keratins: Biomarkers and modulators of apoptotic and necrotic cell death in the liver. Hepatology (2016) 0.80
Canine liver transplantation model and the intermediate filaments of the cytoskeleton of the hepatocytes. J Biomed Biotechnol (2012) 0.78
Keratin 8 variants are infrequent in patients with alcohol-related liver cirrhosis and do not associate with development of hepatocellular carcinoma. BMC Gastroenterol (2012) 0.77
Epithelial Intermediate Filaments: Guardians against Microbial Infection? Cells (2016) 0.77
Human keratin 8 variants promote mouse acetaminophen hepatotoxicity coupled with c-jun amino-terminal kinase activation and protein adduct formation. Hepatology (2015) 0.76
Complementary roles of specific cysteines in keratin 14 toward the assembly, organization, and dynamics of intermediate filaments in skin keratinocytes. J Biol Chem (2015) 0.76
Keratin impact on PKCδ- and ASMase-mediated regulation of hepatocyte lipid raft size - implication for FasR-associated apoptosis. J Cell Sci (2016) 0.76
Telomere shortening as genetic risk factor of liver cirrhosis. World J Gastroenterol (2015) 0.75
Keratin 18, Apoptosis, and Liver Disease in Children. Curr Pediatr Rev (2011) 0.75
High-Throughput Screening for Drugs that Modulate Intermediate Filament Proteins. Methods Enzymol (2015) 0.75
Clinical Applicability of Whole-Exome Sequencing Exemplified by a Study in Young Adults with the Advanced Cryptogenic Cholestatic Liver Diseases. Gastroenterol Res Pract (2017) 0.75
Keratin 8 variants are associated with cryptogenic hepatitis. Virchows Arch (2012) 0.75
Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med (1999) 5.32
Human cell surface glycoprotein related to cell proliferation is the receptor for transferrin. Proc Natl Acad Sci U S A (1981) 4.34
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med (2000) 3.74
"Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet (1994) 3.33
Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci U S A (1999) 3.30
Molecular virology and pathogenesis of hepatitis B. Lancet (1993) 3.27
Biosynthesis of the human transferrin receptor in cultured cells. J Biol Chem (1981) 2.83
Molecular complexity of leukocyte surface glycoproteins related to the macrophage differentiation antigen Mac-1. J Exp Med (1981) 2.66
HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol (2000) 2.60
Human homologue of murine T200 glycoprotein. J Exp Med (1980) 2.57
Covalent binding of fatty acid to the transferrin receptor in cultured human cells. J Biol Chem (1981) 2.51
Effect of sulindac on sporadic colonic polyps. Gastroenterology (1995) 2.27
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg (1997) 2.16
Disposition of T200 glycoprotein in the plasma membrane of a murine lymphoma cell line. J Biol Chem (1980) 2.01
Human cell-surface glycoprotein with unusual properties. Nature (1980) 1.94
Gastrointestinal Kaposi's sarcoma in patients with acquired immunodeficiency syndrome. Endoscopic and autopsy findings. Gastroenterology (1985) 1.90
Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology (2000) 1.84
Acute hepatitis C. Hepatology (2001) 1.82
Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. J Clin Invest (1996) 1.81
Phosphorylation of human keratin 18 serine 33 regulates binding to 14-3-3 proteins. EMBO J (1998) 1.80
Apoptosis generates stable fragments of human type I keratins. J Biol Chem (1997) 1.72
Chronic hepatitis, hepatocyte fragility, and increased soluble phosphoglycokeratins in transgenic mice expressing a keratin 18 conserved arginine mutant. J Cell Biol (1995) 1.71
The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg (1997) 1.68
The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation (1995) 1.67
T200 cell surface glycoprotein of the mouse. Polymorphism defined by the Ly-5 system of alloantigens. J Exp Med (1980) 1.66
Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J Clin Invest (1991) 1.64
The cytoskeleton of digestive epithelia in health and disease. Am J Physiol (1999) 1.61
A controlled study of hepatitis C transmission by organ transplantation. The New England Organ Bank Hepatitis C Study Group. Lancet (1995) 1.54
Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat (2004) 1.52
Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases. Gut (2003) 1.51
Are infectious agents involved in primary biliary cirrhosis? A PCR approach. J Hepatol (1999) 1.50
Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology (2001) 1.49
14-3-3 proteins associate with phosphorylated simple epithelial keratins during cell cycle progression and act as a solubility cofactor. J Cell Biol (1996) 1.48
Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. Hepatology (1999) 1.48
Nitric oxide-induced mutations in the HPRT gene of human lymphoblastoid TK6 cells and in Salmonella typhimurium. Environ Mol Mutagen (2000) 1.46
Are HCV-infected individuals candidates for hepatitis A vaccine? Lancet (1998) 1.46
Characterization of non-transferrin-bound iron clearance by rat liver. J Biol Chem (1986) 1.46
Intermediate filaments take the heat as stress proteins. Trends Cell Biol (2010) 1.44
Susceptibility to hepatotoxicity in transgenic mice that express a dominant-negative human keratin 18 mutant. J Clin Invest (1996) 1.43
Characterization and dynamics of O-linked glycosylation of human cytokeratin 8 and 18. J Biol Chem (1992) 1.43
Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure. Hepatology (1992) 1.41
Hepatitis C and liver transplantation. J Hepatol (2001) 1.40
Pruritus as a symptom of hepatitis C. J Am Acad Dermatol (1994) 1.39
Keratins turn over by ubiquitination in a phosphorylation-modulated fashion. J Cell Biol (2000) 1.33
Recombinational repair is critical for survival of Escherichia coli exposed to nitric oxide. J Bacteriol (2001) 1.33
Regulation of prostaglandin biosynthesis by nitric oxide is revealed by targeted deletion of inducible nitric-oxide synthase. J Biol Chem (2000) 1.32
Efficient clearance of non-transferrin-bound iron by rat liver. Implications for hepatic iron loading in iron overload states. J Clin Invest (1985) 1.32
Fetal microchimerism alone does not contribute to the induction of primary biliary cirrhosis. Hepatology (1999) 1.30
The epidemiology and prevention of hepatocellular carcinoma. Semin Oncol (2001) 1.30
A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology (2001) 1.29
Identification of the major physiologic phosphorylation site of human keratin 18: potential kinases and a role in filament reorganization. J Cell Biol (1994) 1.29
A significant soluble keratin fraction in 'simple' epithelial cells. Lack of an apparent phosphorylation and glycosylation role in keratin solubility. J Cell Sci (1993) 1.28
Role of interferon in homologous and heterologous rotavirus infection in the intestines and extraintestinal organs of suckling mice. J Virol (2008) 1.28
Stress, apoptosis, and mitosis induce phosphorylation of human keratin 8 at Ser-73 in tissues and cultured cells. J Biol Chem (1997) 1.27
Mutation of human keratin 18 in association with cryptogenic cirrhosis. J Clin Invest (1997) 1.24
Liver transplantation for patients with hepatitis B: what have we learned from our results? Hepatology (1991) 1.21
A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotype. Am J Gastroenterol (2000) 1.21
Mutation of a major keratin phosphorylation site predisposes to hepatotoxic injury in transgenic mice. J Cell Biol (1998) 1.20
Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology (1996) 1.19
Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology (1996) 1.17
Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus. Gastroenterology (2000) 1.17
Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology (1999) 1.17
Dynamics of human keratin 18 phosphorylation: polarized distribution of phosphorylated keratins in simple epithelial tissues. J Cell Biol (1995) 1.16
Implications of intermediate filament protein phosphorylation. Cancer Metastasis Rev (1996) 1.16
Failure to detect hepatitis C virus genome in human secretions with the polymerase chain reaction. Hepatology (1991) 1.15
Phosphorylation of human keratin 8 in vivo at conserved head domain serine 23 and at epidermal growth factor-stimulated tail domain serine 431. J Biol Chem (1997) 1.15
Hepatocyte cytokeratins are hyperphosphorylated at multiple sites in human alcoholic hepatitis and in a mallory body mouse model. Am J Pathol (2000) 1.14
Quantitation of hepatitis G and C viruses in the liver: evidence that hepatitis G virus is not hepatotropic. Hepatology (1998) 1.11
HBV core sequence: definition of genotype-specific variability and correlation with geographical origin. J Viral Hepat (2004) 1.11
The 70-kDa heat shock proteins associate with glandular intermediate filaments in an ATP-dependent manner. J Biol Chem (1995) 1.11
Empigen BB: a useful detergent for solubilization and biochemical analysis of keratins. Biochem Biophys Res Commun (1995) 1.10
Characterization of hepatitis G virus (GB-C virus) particles: evidence for a nucleocapsid and expression of sequences upstream of the E1 protein. J Virol (1998) 1.09
Effect of mutation and phosphorylation of type I keratins on their caspase-mediated degradation. J Biol Chem (2001) 1.09
Mitotic arrest-associated enhancement of O-linked glycosylation and phosphorylation of human keratins 8 and 18. J Biol Chem (1993) 1.08
Heat stress or rotavirus infection of human epithelial cells generates a distinct hyperphosphorylated form of keratin 8. Exp Cell Res (1995) 1.07
Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology (1998) 1.05
Protein phosphatase inhibition in normal and keratin 8/18 assembly-incompetent mouse strains supports a functional role of keratin intermediate filaments in preserving hepatocyte integrity. Hepatology (1998) 1.04
Hepatitis C viral infection in liver transplant recipients. Hepatology (1992) 1.04
Hepatitis C virus: quantitation and distribution in liver. J Med Virol (1997) 1.03
Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center. Hepatology (2001) 1.03
Simple epithelial keratins are dispensable for cytoprotection in two pancreatitis models. Am J Physiol Gastrointest Liver Physiol (2000) 1.03
Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother (2002) 1.03
Hepatitis C and liver transplantation. Gut (1999) 1.03
Altered sodium-hydrogen exchange activity is a mechanism for acid-induced hyperproliferation in Barrett's esophagus. Am J Physiol (1998) 1.02
Identification and mutational analysis of the glycosylation sites of human keratin 18. J Biol Chem (1995) 1.02
Mitotic arrest with anti-microtubule agents or okadaic acid is associated with increased glycoprotein terminal GlcNAc's. J Cell Sci (1994) 1.01
Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease. Epilepsia (1999) 1.01
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Transplantation (1998) 1.00
Bile salts induce or blunt cell proliferation in Barrett's esophagus in an acid-dependent fashion. Am J Physiol Gastrointest Liver Physiol (2000) 1.00
Disturbances in hepatic cell-cycle regulation in mice with assembly-deficient keratins 8/18. Hepatology (2001) 0.99
Acid modulation of HT29 cell growth and differentiation. An in vitro model for Barrett's esophagus. J Cell Sci (1997) 0.98
Monoclonal antibodies to a human T-cell antigen and Ia-like antigen in the characterization of lymphoid leukemia. Transplant Proc (1981) 0.98
Cholestatic hepatitis C in liver allografts. Liver Transpl Surg (1998) 0.97
Src activation in malignant and premalignant epithelia of Barrett's esophagus. Gastroenterology (1997) 0.97
Molecular markers of Epstein-Barr virus infection in the circulation of transplant recipients. Transplant Proc (1995) 0.96
Hepatitis G virus infection in patients with hepatitis C virus infection undergoing liver transplantation. Gastroenterology (1996) 0.96
Fibrosing cholestatic hepatitis in patient with HIV and hepatitis B. Lancet (1993) 0.96